BNTC Stock Analysis: Buy, Sell, or Hold?
BNTC - Benitec Biopharma Inc. Common Stock
$12.17
-0.44 (-3.49%)
▼
5d:
-7.66%
30d:
+18.5%
90d:
-3.03%
HOLD
LOW Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 13, 2026
13d
Get Alerted When BNTC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BNTC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: BNTC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: BNTC is currently trading at $12.17, which is considered fair relative to its 30-day fair value range of $10.65 to $13.06.
Technical Outlook: Technically, BNTC is in a downtrend. The price is currently testing key support at $12.17. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.17 (+98.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BNTC is in a downtrend. The price is currently testing key support at $12.17. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.17 (+98.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$10.65 -
$13.06
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 98.6% below Wall St target ($24.17)
- CAUTION: Recommendation downgraded due to -7.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$10.65 -
$13.06
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$1.46
(12.0%)
Support & Resistance Levels
Support Level
$12.17
Resistance Level
$14.33
Current Trend
Downtrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.82
Wall Street Target
$24.17
(+98.6%)
Revenue Growth (YoY)
12.5%
Share & Embed Analysis
Last updated: April 29, 2026 8:46 AM ET
Data refreshes hourly during market hours. Next update: 9:46 AM
Data refreshes hourly during market hours. Next update: 9:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BNTC showing a specific setup today?
Insider Activity (6 Months)
7
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Suvretta Capital Managem…
BUY
77387 shares
2025-12-29
Suvretta Capital Managem…
BUY
16836 shares
2025-12-26
Suvretta Capital Managem…
BUY
50000 shares
2025-12-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 60 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 57 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 67 BUY |
